Notable Downgrades: Extreme Networks (EXTR), Youku Tudou (YOKU), Care.com (CRCM), Keryx Biopharmaceuticals (KERX)

Analysts at Raymond James downgraded Extreme Networks Inc. (EXTR) from ‘Outperform‘ to ‘Market Perform‘ in a research report issued to clients on Friday.

On valuation measures, Extreme Networks Inc. stock it’s trading at a forward P/E multiple of 11.40x.  The t-12-month revenue at Extreme Networks is $580.54 million. EXTR ‘s ROE for the same period is (46.29%).

Shares of the $329.18 million market cap company are down 37.97% year-over-year  and 1.42% year-to-date.

Extreme Networks Inc., currently with a median Wall Street price target of $5.00 and a high target of $6.00, dropped $0.17 to $3.31 in recent trading.

The chart below shows where the equity has traded over the past 52-weeks.

Youku Tudou Inc. (YOKU) was reiterated a ‘Buy’ by Brean Capital analysts on Friday. The broker also cut its price target on the stock to $20 from $24, implying 16.60% expected downside.

On valuation measures, Youku shares have a PEG ratio of (0.67). T-12 price/sales is 5.12 while EPS is ($0.52). Currently there are 4 analysts that rate YOKU a ‘Buy’, 6 rate it a ‘Hold’. No analyst rates it a ‘Sell’. YOKU has a median Wall Street price target of $23.00 with a high target of $27.00.

In the past 52 weeks, shares of the Beijing, China-based Internet television company have traded between a low of $13.56 and a high of $30.95 and are now at $13.65. Shares are down 49.30% year-over-year and 14.94% year-to-date.

Care.com, Inc. (CRCM) was reiterated as ‘Buy’ with a $9 from $11 price target on Friday by Needham.

CRCM shares recently lost $0.40 to $7.37. In the past 52 weeks, shares of Waltham, Massachusetts-based company have traded between a low of $6.50 and a high of $18.37. Shares are down 58.54% year-over-year, compared with an 11.93% gain in the S&P 500.

Keryx Biopharmaceuticals Inc. (KERX) rating of ‘Outperform’ was reiterated today at Oppenheimer with a price target decrease of $18 from $22 (versus a $13.63 previous close).

KERX shares recently gained $0.70 to $14.33. Oppenheimer’s target price suggests a potential downside of about 28% from ticker’s current $14.44 price.

In the past 52 weeks, shares of the New York-based firm have traded between a low of $10.85 and a high of $18.48. Shares are down 10.51% year-over-year and 3.67% year-to-date.